Skip to main content
SpringerLink
Log in

Ramipril is well established in hypertension

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993 Apr 10; 306: 983–7

    Article  PubMed  CAS  Google Scholar 

  2. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of the 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 1993 Dec 11; 307: 1541–6

    Article  Google Scholar 

  3. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153: 154–83

    Article  Google Scholar 

  4. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs 1995 Apr; 49(4): 516–35

    Article  PubMed  CAS  Google Scholar 

  5. Frampton JE, Peters DH. Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995 Mar; 49(3): 440–66

    Article  PubMed  CAS  Google Scholar 

  6. Genthon R, and the ATHES study group. Study of the efficacy and safety of the combination ramipril 2.5mg plus hydrochlorothiazide 12.5mg in patients with mild-to-moderate hypertension. Int J Clin Pharmacol Res 1994; 14: 1–9

    PubMed  CAS  Google Scholar 

  7. Heidbreder D, Froer K-L, Breitstadt A, et al. Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1 — a double-blind, comparative, multicenter study in non-responders to ramipril monotherapy. Clin Cardiol 1992; 15: 904–10

    Article  PubMed  CAS  Google Scholar 

  8. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993; 11: 217–21

    Article  PubMed  CAS  Google Scholar 

  9. Amery A, Kiowski W, Löffler K, et al. Double-blind comparison of ramipril, piretanide and the combined therapy in hypertensive patients [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: 131

    Google Scholar 

  10. Brandt D. Therapie der arteriellen hypertonie mit dem ACE-hemmer ramipril: ergebnisse der Ostereichsichen multicenter-ramipril-studie (ART1). Therapiewoche Osterreich 1992; 7: 394–400

    Google Scholar 

  11. Carré A, Vasmant D, Elmalem J, et al. Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice. J Cardiovasc Pharmacol 1991; 18 Suppl. 2: 141–3

    Google Scholar 

  12. Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. Clin Ther 1993; 15: 810–8

    PubMed  CAS  Google Scholar 

  13. Reinisch W, Hoffmann H, Hoffmann W. Hypertension treatment with ramipril: results of a prospective clinical study [in German]. Ther Schweiz 1993; 9: 655–9

    Google Scholar 

  14. Lonati L, Sampieri L, Cuspudi C. Efficacy and safety of ramipril in elderly hypertensive patients: a multicenter trial [abstract]. Presented at: IFECC III International Forum for the Evaluation of Cardiovascular Care, Monte Carlo, Jan 19–22, 1994

  15. Schreiner M, Berendes B, Verho M, et al. Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1991; 18 Suppl. 2: 137–40

    Google Scholar 

  16. Schwartz SL, Hanson C, Lucas C, et al. Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension. Clin Ther 1993; 17: 79–87

    Google Scholar 

  17. Kindler J, Schunkert H, Gassmann M, et al. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure. J Cardiovasc Pharmacol 1989; 13 Suppl 3; S55–8

    Article  PubMed  Google Scholar 

  18. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993 Oct 2; 342: 821–8

    Google Scholar 

  19. Add ACE inhibitors to the range of treatment options post-MI. Drug Ther Perspect 1995 Jun 12; 5(11): 9–11

    Google Scholar 

  20. Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma and broncho-spasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308: 18–21

    Article  PubMed  CAS  Google Scholar 

  21. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 82–5

  22. Hoyer J, Schulte K-L, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 1993 Mar; 24(3): 230–54

    Article  PubMed  CAS  Google Scholar 

  23. 1995 Physicians Genrx. St. Louis, Missouri: Mosby-Year Book, Inc., 1995

  24. Cody RJ. Optimising ACE inhibitor therapy of congestive heart failure. Clin Pharmacokinet 1993; 24(1): 59–70

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramipril is well established in hypertension. Drugs Ther. Perspect 5, 1–4 (1995). https://doi.org/10.2165/00042310-199505110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505110-00001

Keywords

Search

Navigation